Biocon Biologics Profile
Key Indicators
- Authorised Capital ₹ 3,500.00 Cr
as on 31-12-2024
- Paid Up Capital ₹ 1,758.31 Cr
as on 31-12-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 16,501.50 Cr
as on 31-12-2024
- Satisfied Charges ₹ 10,141.76 Cr
as on 31-12-2024
- Revenue 21.86%
(FY 2022)
- Profit -58.99%
(FY 2022)
- Ebitda -7.01%
(FY 2022)
- Net Worth 3.48%
(FY 2022)
- Total Assets 7.46%
(FY 2022)
About Biocon Biologics
The Corporate was formerly known as Biocon Biologics India Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3,500.00 Cr and a paid-up capital of Rs 1,758.31 Cr.
The company currently has active open charges totaling ₹16,501.50 Cr. The company has closed loans amounting to ₹10,141.76 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Biocon Biologics Limited India are Shreehas Tambe as Ceo, Akhilesh Nand as Company Secretary, and Mr Upadhye as Cfo. Bobby Parikh, Rajiv Malik, Daniel Bradbury, and Seven other members serve as directors at the Company.
- CIN/LLPIN
U24119KA2016PLC093936
- Company No.
093936
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2016
- Date of AGM
26 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Biocon Biologics?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shreehas Tambe  | Managing Director | 05-Dec-2022 | Current |
| Akhilesh Nand | Company Secretary | 21-Aug-2024 | Current |
| Mr Upadhye | CFO | Current |
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nivruti Rai  | Director | 01-Aug-2019 | Current |
| Kiran Shaw | Whole-Time Director | 08-Jun-2016 | Current |
| Daniel Bradbury | Director | 01-Aug-2019 | Current |
| Bobby Parikh | Director | 01-Aug-2019 | Current |
| Rajiv Malik | Nominee Director | 29-Nov-2022 | Current |
Peter Piot  | Director | 21-Jan-2021 | Current |
Financial Performance of Biocon Biologics.
Biocon Biologics Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 21.86% increase. The company also saw a substantial fall in profitability, with a 58.99% decrease in profit. The company's net worth moved up by a moderate rise of 3.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biocon Biologics?
In 2023, Biocon Biologics had a promoter holding of 92.04% and a public holding of 7.96%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 09 Dec 2024 | ₹847.30 Cr | Open |
Others Creation Date: 22 Nov 2024 | ₹6,808.76 Cr | Open |
Others Creation Date: 03 Mar 2023 | ₹7,947.94 Cr | Open |
How Many Employees Work at Biocon Biologics?
Biocon Biologics has a workforce of 5280 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biocon Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biocon Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
